Intellia Therapeutics (NTLA) Q4 results:
Revenues: $10.9M (+38.0%).
Net loss: ($28.3M) (-48.2%); loss/share: ($0.57) (-32.6%); Quick Assets: $284.5M (-9.4%).
The company plans to submit an IND application for NTLA-5001 for the treatment of acute myeloid leukemia in H1 2021.
Shares are down 1% premarket.
Previously: Intellia Therapeutics EPS in-line, beats on revenue (Feb. 27)
https://seekingalpha.com/news/3546485-intellia-therapeutics-q4-top-line-up-38
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.